Pidnarulex plus cemiplimab for MSS colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two drugs together: pidnarulex (a targeted therapy) and cemiplimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced colorectal cancer that is microsatellite stable (MSS) and has not responded to current treatments, especially if their tumor has a MYC or FBXW7 change.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread and cannot be removed by surgery, and standard treatments are no longer working for you.
- Your tumor is microsatellite stable (MSS) or has normal mismatch repair (pMMR).
- You have already tried at least these standard treatments: fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and an EGFR inhibitor (like cetuximab or panitumumab).
- For the Phase 2 part of the study, you must have at least one cancer spot in your liver and a tumor that can be biopsied.
- Your tumor must have either a MYC gene amplification or an FBXW7 gene mutation (from earlier testing).
- You are generally in good health, with adequate organ function (kidney, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy combination for older patients with a specific type of colorectal cancer that has not been treated before. The goal is to see if these drugs can help the immune system fight the cancer without needing surgery or standard chemotherapy.
This trial tests a new drug called CX-5461 (also known as pidnarulex) in people whose cancer has spread and hasn't been helped by standard treatments. It looks at how your body responds to the drug, which may target cancers with specific DNA repair problems.
This trial tests a combination of two new drugs, BND-22 and cemiplimab, for people with certain advanced solid tumors like lung, colorectal, or ovarian cancer. It aims to see if this treatment helps control the cancer and looks at specific markers in your blood and tissue.
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
This trial is for people with colorectal cancer whose ctDNA blood test is still positive after surgery and chemotherapy. It tests two immunotherapy drugs (cemiplimab alone or with fianlimab) to see if they can eliminate the remaining cancer cells and prevent the cancer from coming back.
This trial tests adding immunotherapy to standard chemotherapy and targeted therapy for people with metastatic colorectal cancer that is MSS (microsatellite stable) and cannot be removed with surgery. It aims to see if this combination helps shrink tumors and improve outcomes.
Hear when a new Metastatic Colorectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.